Anti-Ceramide ScFv Prophylaxis for First Responders to a Limited Nuclear Attack.

Area of Science:

• Radiation biology
• Medical countermeasures
• Gastrointestinal radiation injury

Background:

• Post-9/11 initiatives focus on medical countermeasures (MRCs) for acute radiation syndromes (ARS).
• Hematopoietic-ARS is treatable, but effective GI-ARS mitigation is lacking.
• GI-ARS poses a significant threat following limited nuclear attacks.

Purpose of the Study:

• To evaluate CX-01, a humanized anti-ceramide single-chain variable fragment (scFv), as a prophylactic MRC for GI-ARS.
• To assess the efficacy of CX-01 in preventing radiation-induced lethality in a mouse model.
• To determine optimal administration and dosage for CX-01 in potential first responders.

Main Methods:

• Pre-treatment with anti-ceramide scFv (CX-01) was administered to mice prior to irradiation.
• Efficacy was assessed by measuring prevention of small intestinal endothelial apoptosis and lethality.
• CX-01 administration routes (subcutaneous, intramuscular) and dose-response in males versus females were investigated.

Main Results:

• CX-01 pre-treatment up to 90 minutes before irradiation prevented GI-ARS lethality in mice.
• Females required approximately twice the CX-01 dose compared to males for full protection.
• CX-01 demonstrated effectiveness via subcutaneous and intramuscular routes, crucial for battlefield application.

Conclusions:

• CX-01 is a promising prophylactic medical countermeasure against GI-ARS.
• Further structural modifications may be needed to extend CX-01's half-life for optimal first responder use.
• CX-01 represents a significant advancement in protecting against radiation exposure.